Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Tasha N. Sims"'
Autor:
Takahiro Ebata, Yutaka Fujiwara, Shunsuke Kondo, P. Rietschel, Noboru Yamamoto, Tasha N. Sims, Toshio Shimizu, Akihiko Shimomura, Siyu Li, Anne Paccaly, Takafumi Koyama, Satoru Iwasa, Shigehisa Kitano
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced malignancies. Methods Patients receiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a5b9dd2b9d5efe0f5a9e057818c12ac
https://doi.org/10.1007/s00280-020-04161-6
https://doi.org/10.1007/s00280-020-04161-6
Autor:
Jason J. Luke, Steven J. Chmura, Tasha N. Sims, Israel Lowy, Yang Xin Fu, Helena J. Mauceri, Ainhoa Arina, Wenxin Zheng, Christian A. Fernandez, Nikolai N. Khodarev, Sean P. Pitroda, Byron Burnette, Yuzhu Hou, Martin Forde, Ralph R. Weichselbaum, Michael A. Beckett
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-13 (2019)
Nature Communications
Nature Communications
Successful combinations of radiotherapy and immunotherapy depend on the presence of live T cells within the tumor; however, radiotherapy is believed to damage T cells. Here, based on longitudinal in vivo imaging and functional analysis, we report tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f736995ec3a7c15454e792ded9ec259
http://link.springer.com/article/10.1038/s41467-019-11906-2
http://link.springer.com/article/10.1038/s41467-019-11906-2
Autor:
Paul J. Catalano, Tasha N. Sims, Sabine Mueller, Amy-Lee Bredlau, Cassie Kline, Michael D. Prados, Jingjin Li, Jonathan D. Schoenfeld, Anne Paccaly, Daphne A. Haas-Kogan
Publikováno v:
Neuro Oncol
DIPG and HGG lead to the majority of pediatric cancer-related deaths. Despite multimodal treatment, the 2-year survival rates for DIPG and HGG are less than 10% and 20%, respectively. Anti-PD-1 therapy combined with radiotherapy has demonstrated syne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::baffbb0ff9d5b3d4d83f34063b38473f
https://europepmc.org/articles/PMC6847516/
https://europepmc.org/articles/PMC6847516/
Autor:
Ding Wang, Sang-We Kim, Melissa Lynne Johnson, John M. Kaczmar, Guilherme Rabinowits, Tasha N. Sims, Meredith McKean, Stephen K. Williamson, Tae Min Kim, Nehal Lakhani, Jayakumar Mani, Alexander I. Spira, Roman Groisberg, Kyriakos P. Papadopoulos, Mark R. Middleton, Rodolfo Gutierrez, James Cassidy, Omid Hamid, Shuquan Chen, Glenn Kroog
Publikováno v:
Journal of Clinical Oncology. 39:9515-9515
9515 Background: Fianlimab and cemiplimab are two high-affinity, fully human, hinge-stabilized IgG4 monoclonal antibodies. In a Phase 1 dose escalation study, fianlimab combined with cemiplimab showed an acceptable safety profile and some clinical ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e07e5f089528c20417567060a1bade05
https://doi.org/10.1200/jco.2021.39.15_suppl.9515
https://doi.org/10.1200/jco.2021.39.15_suppl.9515
Autor:
Sumati Gupta, Srabani Bhaumik, Yolanda D. Mahnke, Kavita M. Dhodapkar, Ruslan D. Novosiadly, Cristina Maccalli, Yoshinobu Koguchi, Amanda W. Lund, Jean-Charles Grivel, Holden T. Maecker, Brent A. Hanks, Sylvia Janetzki, Siwen Hu-Lieskovan, Senthamil R. Selvan, Thomas O. Kleen, Tasha N. Sims, Yingdong Zhao
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Since the publication of the Society for Immunotherapy of Cancer’s (SITC) original cancer immunotherapy biomarkers resource document, there have been remarkable breakthroughs in cancer immunotherapy, in particular the development and approval of im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b1b180e0a72da50f3e205946ea5a1f7
https://doi.org/10.1136/jitc-2020-000705
https://doi.org/10.1136/jitc-2020-000705
Autor:
Huanyu Chen, Glenn Kroog, Tasha N. Sims, Robert G. Maki, Ding Wang, Maria Karasarides, Kyriakos P. Papadopoulos, Derrick Bramble, Afshin Dowlati, Min Zhu, Karen Kelly, Melissa Lynne Johnson, Filipa Lynce, Amy-Lee Bredlau, Ana Gonzalez Ortiz, Haeseong Park, Nehal Lakhani, Timothy A. Yap, Susanna Varkey Ulahannan
Publikováno v:
Journal of Clinical Oncology. 37:2508-2508
2508 Background: We present initial safety, pharmacokinetics (PK), and efficacy from the dose escalation study of R3767, alone (mono) or in combination with cemiplimab (REGN2810), a PD-1 mAb (combo), in pts with advanced malignancies (NCT03005782). M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a4a3c76a37115794b1c0628f4e00c19
https://doi.org/10.1200/jco.2019.37.15_suppl.2508
https://doi.org/10.1200/jco.2019.37.15_suppl.2508
Autor:
Akihiko Shimomura, Shunsuke Kondo, Satoru Iwasa, Yutaka Fujiwara, P. Rietschel, Toshio Shimizu, Tasha N. Sims, Anne Paccaly, Siyu Li, Takafumi Koyama, Noboru Yamamoto, Shigehisa Kitano, Takahiro Ebata, Clifford Baum
Publikováno v:
Journal of Clinical Oncology. 37:33-33
33 Background: Cemiplimab (REGN2810), a high-affinity, highly potent, human monoclonal antibody to PD-1, has demonstrated a safety profile comparable with that of other anti-PD-1 antibodies and antitumor activity in various solid tumors including cut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::285e122463f416777e23130c46325fce
https://doi.org/10.1200/jco.2019.37.8_suppl.33
https://doi.org/10.1200/jco.2019.37.8_suppl.33
Autor:
Kristina Somersalo, Kenneth G. Johnson, Paul M. Allen, W R Burack, Tasha N. Sims, Michael L. Dustin, Shannon K. Bromley, Mark M. Davis, Andrey S. Shaw, C Sumen
The adaptive immune response is initiated by the interaction of T cell antigen receptors with major histocompatibility complex molecule-peptide complexes in the nanometer scale gap between a T cell and an antigen-presenting cell, referred to as an im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::542c9d06feb433c670172d76cde747a7
https://ora.ox.ac.uk/objects/uuid:2101d7aa-d2c8-439c-9749-33101bd97689
https://ora.ox.ac.uk/objects/uuid:2101d7aa-d2c8-439c-9749-33101bd97689
Autor:
Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Nehal Lakhani, Glenn Kroog, Maria Karasarides, Haeseong Park, Timothy A. Yap, Chetachi Emeremni, Kathleen N. Moore, Ding Wang, Tasha N. Sims
Publikováno v:
Journal of Clinical Oncology. 36:TPS3127-TPS3127
TPS41 Background: Lymphocyte activation gene 3 (LAG-3) is an immune checkpoint receptor with a biological role in T-cell regulation. Analysis of immune-cell infiltrates from human tumors show that a subset of CD4+ and/or CD8+ cells co-express LAG-3 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8890ef25efc926bc821c12cb5cf39e11
https://doi.org/10.1200/jco.2018.36.15_suppl.tps3127
https://doi.org/10.1200/jco.2018.36.15_suppl.tps3127
Autor:
Michael L. Dustin, Tasha N. Sims
Publikováno v:
Immunological Reviews. 186:100-117
Adhesive interactions play important roles in coordinating T-cell migration and activation, specifically in the formation of the immunological synapse (IS), a specialized cell-cell junction. Recent demonstrations show several molecules implicated in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9820d46f14474b9641c472bcc37f3b0b
https://doi.org/10.1034/j.1600-065x.2002.18610.x
https://doi.org/10.1034/j.1600-065x.2002.18610.x